Geographical variation of medicated Parkinsonism in Finland during 1995 to 2000

Movement Disorders

Volumn 23, Issue 7, 2008, Pages 1024-1031

  Havulinna, Aki S ^a,b   Tienari, Pentti J ^c   Marttila, Reijo J ^d   Martikainen, Kirsti K ^e   Eriksson, Johan G ^a,c   Taskinen, Olli ^a   Moltchanova, Elena ^a   Karvonen, Marjatta ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b AALTO UNIVERSITY   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e The Finnish Parkinson Association and Foundation   (Finland)

Author keywords

Bayesian analysis; Geographic variation; Incidence studies; Parkinsonism; Prevalence studies

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; SELEGILINE; ANTIPARKINSON AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; FINLAND; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SEX RATIO; TREND STUDY; URBAN RURAL DIFFERENCE; DRUG THERAPY; MIDDLE AGED; REGISTER; RESIDENTIAL CARE; RURAL POPULATION; STATISTICS; URBAN POPULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CATCHMENT AREA (HEALTH); DRUG THERAPY; FEMALE; FINLAND; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; PREVALENCE; REGISTRIES; RURAL POPULATION; URBAN POPULATION;

EID: 49249139730     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22024     Document Type: Article

References (24)

1. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. European community concerted action on the epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:10-15.
2. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Environmental risk factors in Parkinson's disease. Mov Disord 1999;14:928-939.
3. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 2001;86:122-127.
4. Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J. Body mass index and the risk of Parkinson disease Neurology 2006;67:1955-1959.
5. Sveinbjornsdottir S, Hicks AA, Jonsson T, et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 2000; 343:1765-1770.
6. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999;45:577-582.
7. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol 2006;60:389-398.
8. Bonifati V. Parkinson's disease: the LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics. Eur J Hum Genet 2006;14:1061-1062.
9. Rytkonen M, Ranta J, Tuomilehto J, Karvonen M,for the SPAT Study Group and the Finnish Childhood Diabetes Registry Group. Bayesian analysis of geographical variation in the incidence of Type I diabetes in Finland. Diabetologia 2001;44[suppl 3]:B37-B44.
10. Keranen R, Malinen P, Keranen H, Heiskanen T. Suomen maaseututyyppien alueellistaminen. Research report 6:1. Ylä-Savon Instituutti, Sonkajarvi, Finland. In Finnish.
11. Keranen H, Malinen P, Aulaskari O. Suomen maaseututyypit. Research Papers 20. Finnish Regional Research, Sonkajärvi, Finland. In Finnish. Available at: http://www.aluekehityssaatio.fi/far/ ?download=selvityksia20.pdf. Accessed January 28, 2008.
12. National Cancer institute: "SEER standard populations", available at http://seer.cancer.gov/stdpopulations/stdpop.19ages.html. Accessed January 28, 2008.
13. Besag J, York J, Mollié A. Bayesian image restoration, with two applications in spatial statistics. Ann Inst Statist Math 1991;43: 1-59.
14. Karvonen M, Moltchanova E, Viik-Kajander M, et al. Regional inequality in the risk of acute myocardial infarction in Finland: a case study of 35- to 74-year-old men. Heart Drug 2002;2:51-60.
15. Spiegelhalter D, Thomas A, Best N, Lunn D. 2004. WinBUGS Version 1.4.1 User Manual. Cambridge, UK: MRC Biostatistics Unit. Available at: http://www.mrc-bsu.cam.ac.uk/bugs. Accessed January 28, 2008.
16. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003;18:19-31.
17. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam study. Neurology 2004;63:1240-1244.
18. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord 2007;22:2242-2248.
19. Norio R. Finnish Disease Heritage I: characteristics, causes, background. Hum Genet 2003;112:441-456.
20. Lappalainen T, Koivumaki S, Salmela E, et al. Regional differences among the Finns: a Y-chromosomal perspective. Gene 2006; 376:207-215.
21. Timonen S, Uotila U, Kuusisto P, Vara P, Lokki O: effect of certain maternal, foetal and geographical factors on the weight and length of the newborn and on the duration of pregnancy. Annales Chirurgiae et Gynaecologiae Fenniae 1966;55:196-213.
22. Haukka J, Suvisaari J, Varilo T, Lönnqvist J. Regional variation in the incidence of schizophrenia in Finland: a study of birth cohorts bom from 1950 to 1969. Psychol Med 2001;31:1045-1053.
23. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007;62:145-153.
24. Evans W, Fung HC, Steele J, et al. Tau H2 haplotype is almost exclusively Caucasian in origin. Neurosci Lett 2004;369:183-185.